UB Paderborn / Katalog / Suche / in CDI

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

Journal of clinical oncology, 2011-06, Vol.29 (17), p.2342-2349

2011

Link zum Volltext

Verfügbarkeit prüfen

Hispanic breast cancer patients’ symptom experience and patient-physician communication during chemotherapy

Supportive care in cancer, 2019-02, Vol.27 (2), p.697-704

2019

Link zum Volltext

Verfügbarkeit prüfen

The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial

Cancer prevention research (Philadelphia, Pa.), 2021-07, Vol.14 (7), p.753-762

2021

Link zum Volltext

Verfügbarkeit prüfen

Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial

JAMA oncology, 2019-01, Vol.5 (1), p.45

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD9-03: Pam50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the alternate trial (Alliance A011106)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD9-03-PD9-03

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT2-1-04: Alliance A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A phase III study

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.OT2-1-04-OT2-1-04

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT026: The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT026-CT026

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2214: Disparity in the uptake of risk-reducing surgery after GCRA in Hispanic patients in Latin America and in the United States

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.2214-2214

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2761: Evaluation of the BOADICEA model for predicting BRCA1 and BRCA2 mutation carrier probabilities in high-risk US Hispanic and Mexican families: A report from the Clinical Cancer Genetics Community Research Network

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.2761-2761

2015

Link zum Volltext

Verfügbarkeit prüfen

Analysis of the prognosis of minimal and occult breast cancers

Archives of surgery (Chicago. 1960), 1983-12, Vol.118 (12), p.1403

1983

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

Annals of oncology, 2015-07, Vol.26 (7), p.1280-1291

2015

Link zum Volltext

Verfügbarkeit prüfen

Whole―genome analysis informs breast cancer response to aromatase inhibition

Nature (London), 2012-06, Vol.486 (7403), p.353-360

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-423: Whole genome comparisons of pre- and post- aromatase inhibitor treatment in estrogen receptor positive breast cancer

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.LB-423-LB-423

2012

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

Hispanic breast cancer patients’ symptom experience and patient-physician communication during chemotherapy

The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial

Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial

Abstract PD2-10: Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE trial analysis (Alliance A011106)

Abstract GS4-05: Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)

Abstract OT2-1-04: Alliance A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A phase III study

Abstract CT026: The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial

Abstract 2214: Disparity in the uptake of risk-reducing surgery after GCRA in Hispanic patients in Latin America and in the United States

Abstract 2761: Evaluation of the BOADICEA model for predicting BRCA1 and BRCA2 mutation carrier probabilities in high-risk US Hispanic and Mexican families: A report from the Clinical Cancer Genetics Community Research Network

Analysis of the prognosis of minimal and occult breast cancers

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group

Whole―genome analysis informs breast cancer response to aromatase inhibition

Abstract LB-423: Whole genome comparisons of pre- and post- aromatase inhibitor treatment in estrogen receptor positive breast cancer

Suchergebnisse filtern